Examines the emerging therapeutic role of TRPV1

TRPV1 is considered an integrator of noxious stimuli and therefore may be at a crossroads for pain transmission pathways. Because of its potential for managing multiple pain types, including osteoarthritis, chronic low back pain, neuropathic pain, and cancer pain, some consider it "the holy grail" of pain management. This dedicated reference summarizes available data related to the potential therapeutic utility for TRPV1 ligands.

With contributions from many of the world's leading experts on TRP channels, Vanilloid Receptor TRPV1 in Drug Discovery covers the important TRPV1 target for drugs to treat painful conditions such as inflammation, arthritis, and cancer pain. The book discusses:

• Recent advances in biology, chemistry, and pharmacology at both the preclinical and clinical stage of the dynamic area of TRPV1 drug discovery research

• The potential for drugs targeting TRPV1 in painful conditions such as inflammation, arthritis, and cancer

• The development of analgesic drugs

• Other applications for TRPV1, including the treatment of respiratory disease and diabetes

Featuring data relevant to the therapeutic potential of TRPV1 and the medicinal chemistry involved in designing TRPV1 antagonists, Vanilloid Receptor TRPV1 in Drug Discovery is a key tool for researchers in the pharmaceutical industry and academia involved in pain, ion channels, and analgesic drug development.

ARTHUR GOMTSYAN is an Associate Research Fellow at Abbott Laboratories where he focuses on neuroscience research and pain drug targets. He is on the editorial board of two peer-reviewed journals and has over forty scientific articles to his credit.

CONNIE R. FALTYNEK is a Director for Neuroscience and Pain Discovery at Abbott Laboratories. She has twenty years' experience in drug discovery research in the pharmaceutical industry and has published nearly 100 scientific papers.